Last reviewed · How we verify
LC350189 formulated capsule
At a glance
| Generic name | LC350189 formulated capsule |
|---|---|
| Sponsor | LG Chem |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- A Study to Assess Efficay and Safety of LC350189 Different Doses in Gout Patients With Hyperuricemia (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- LC350189 formulated capsule CI brief — competitive landscape report
- LC350189 formulated capsule updates RSS · CI watch RSS
- LG Chem portfolio CI